FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311897987> ?p ?o ?g. }

• W4311897987 endingPage "84" @default.
• W4311897987 startingPage "84" @default.
• W4311897987 abstract "Introduction: Extracorporeal membrane oxygenation (ECMO) has been utilized as a rescue therapy for patients with severe ARDS. Multiple case series have suggested that the duration of veno-venous ECMO support in patients with COVID-19 pneumonia may be longer than patients with ARDS secondary to alternative etiology. However, the impact of longer run of ECMO on patient outcomes are not clear. Methods: This was a retrospective study performed at Mayo Clinic Florida and Mayo Clinic Rochester, tertiary ECMO centers in USA. Analysis includes all consecutive patients who were placed on VV ECMO for COVID-19-induced ARDS between January 2019 to March 2022. The study population was classified into two groups: short term ECMO duration (< 4 weeks) and prolonged ECMO support (>4 weeks). Demographic data, baseline clinical characteristics, treatments administered, mechanical ventilator data, lab data, ECMO data and outcome related data were collected and analyzed. Results: A total of 63 COVID-19 patients were included. For the entire cohort, the 30 day mortality was 6%, the 90 day mortality was 30% and the median duration of ECMO support was 35 days (IQR 38). A total of 6 (10%) patients went on to receive lung transplant. Among these, 25(40%) patients required ECMO for < 4 weeks and 38(60%) patients for >4 weeks. The median SOFA values (13 vs 11, 0.016) for the ≤4 weeks cohort was higher. Both groups received similar COVID-19 therapies: glucocorticoids (96 vs 100%, p=0.397), tocilizumab (52 vs 50%, p=1.000), anti-virals (88 vs 87%, p=1.000), and convalescent plasma (48 vs 45%, p=1.000). The cumulative mortality rates for the 2 groups were 8% vs 5% at 30 days (p=1.0), 12% vs 42% at 60 days (p=0.013), 12% vs 50% at 90 days (p=0.002) and 12% vs 50%(p=0.002) at 180 days. Conclusions: The study demonstrated that a substantial number of COVID19 patients require ECMO for > 4 weeks. In this cohort, the mortality rate in the first 4 weeks of ECMO support was low, at 6%. The patients who required ECMO for >4 weeks were more likely to have higher mortality compared to the patients treated with ECMO for shorter duration." @default.
• W4311897987 created "2023-01-02" @default.
• W4311897987 creator A5000533068 @default.
• W4311897987 creator A5015852963 @default.
• W4311897987 creator A5019025747 @default.
• W4311897987 creator A5031312462 @default.
• W4311897987 creator A5054359032 @default.
• W4311897987 creator A5057370537 @default.
• W4311897987 creator A5061307722 @default.
• W4311897987 creator A5077463295 @default.
• W4311897987 creator A5023131387 @default.
• W4311897987 date "2022-12-15" @default.
• W4311897987 modified "2023-10-18" @default.
• W4311897987 title "200: EXTRACORPOREAL MEMBRANE OXYGENATION IN PATIENTS WITH COVID-19: DURATION AND OUTCOMES" @default.
• W4311897987 doi "https://doi.org/10.1097/01.ccm.0000906536.54551.79" @default.
• W4311897987 hasPublicationYear "2022" @default.
• W4311897987 type Work @default.
• W4311897987 citedByCount "0" @default.
• W4311897987 crossrefType "journal-article" @default.
• W4311897987 hasAuthorship W4311897987A5000533068 @default.
• W4311897987 hasAuthorship W4311897987A5015852963 @default.
• W4311897987 hasAuthorship W4311897987A5019025747 @default.
• W4311897987 hasAuthorship W4311897987A5023131387 @default.
• W4311897987 hasAuthorship W4311897987A5031312462 @default.
• W4311897987 hasAuthorship W4311897987A5054359032 @default.
• W4311897987 hasAuthorship W4311897987A5057370537 @default.
• W4311897987 hasAuthorship W4311897987A5061307722 @default.
• W4311897987 hasAuthorship W4311897987A5077463295 @default.
• W4311897987 hasBestOaLocation W43118979871 @default.
• W4311897987 hasConcept C126322002 @default.
• W4311897987 hasConcept C141071460 @default.
• W4311897987 hasConcept C167135981 @default.
• W4311897987 hasConcept C2776348555 @default.
• W4311897987 hasConcept C2776858399 @default.
• W4311897987 hasConcept C2777714996 @default.
• W4311897987 hasConcept C2777914695 @default.
• W4311897987 hasConcept C2908647359 @default.
• W4311897987 hasConcept C71924100 @default.
• W4311897987 hasConcept C72563966 @default.
• W4311897987 hasConcept C99454951 @default.
• W4311897987 hasConceptScore W4311897987C126322002 @default.
• W4311897987 hasConceptScore W4311897987C141071460 @default.
• W4311897987 hasConceptScore W4311897987C167135981 @default.
• W4311897987 hasConceptScore W4311897987C2776348555 @default.
• W4311897987 hasConceptScore W4311897987C2776858399 @default.
• W4311897987 hasConceptScore W4311897987C2777714996 @default.
• W4311897987 hasConceptScore W4311897987C2777914695 @default.
• W4311897987 hasConceptScore W4311897987C2908647359 @default.
• W4311897987 hasConceptScore W4311897987C71924100 @default.
• W4311897987 hasConceptScore W4311897987C72563966 @default.
• W4311897987 hasConceptScore W4311897987C99454951 @default.
• W4311897987 hasIssue "1" @default.
• W4311897987 hasLocation W43118979871 @default.
• W4311897987 hasLocation W43118979872 @default.
• W4311897987 hasOpenAccess W4311897987 @default.
• W4311897987 hasPrimaryLocation W43118979871 @default.
• W4311897987 hasRelatedWork W2467758200 @default.
• W4311897987 hasRelatedWork W2910638862 @default.
• W4311897987 hasRelatedWork W3030048823 @default.
• W4311897987 hasRelatedWork W3131850829 @default.
• W4311897987 hasRelatedWork W4200134398 @default.
• W4311897987 hasRelatedWork W4200549927 @default.
• W4311897987 hasRelatedWork W4226213757 @default.
• W4311897987 hasRelatedWork W4282961208 @default.
• W4311897987 hasRelatedWork W4367607865 @default.
• W4311897987 hasRelatedWork W3210137592 @default.
• W4311897987 hasVolume "51" @default.
• W4311897987 isParatext "false" @default.
• W4311897987 isRetracted "false" @default.
• W4311897987 workType "article" @default.